Building on its strong growth from 2015, Biomax grew at a double digit rate in 2016. This success was driven by extending contracts with several long term customers as well as attracting new BioXM™ customers in the clinical and pharma sectors. Expanding these new customer relationships will provide Biomax with sustainable growth in the next years.

To adapt the organization to the higher volume of business and maintain high quality, Biomax has significantly expanded its staff in the last two years. The new employees strengthen our expertise in Project Management, Software Development and Quality Assurance.

Vienna-based Biomax subsidiary, Viscovery, has launched version 7.1 of its Viscovery^® SOMine^® data mining suite. In addition to numerous usability improvements, the latest version provides additional functionality to visually explore multivariate Big Data, analyze multiple attribute correlations, determine score groups with maximal response, and display thumbnail images associated to the ordered data records in the Viscovery model map.

Visit the Viscovery website to see an example of how data scientists used the power of the Viscovery Big Data feature to rapidly visualize and explore tens of millions of US mortality records — with surprising results.

At SynBioBeta London 2017, Biomax’ own Dr. John Sgouros recently spoke about the potential of synthetic biology to revolutionize a wide range of industries. He detailed how Biomax helps clients systematically analyze their vast, unstructured data — helping them leverage synthetic biology to optimize the discovery, genetic engineering, and manufacturing processes driving innovation. His insights are highlighted in a recent article featured in GEN, “Synthetic Biology Expands and Grows.”

You can meet Dr. Sgouros at the Digital Health and Care Congress 2017 in London next week. Set up a meeting with him here.

In the current issue of ERJ Open Research, the Mechanisms of the Development of ALLergy (MeDALL) consortium reports on their examination of variations in the prevalence of childhood asthma and wheeze in Europe.

MeDALL researchers deployed the BioXM platform in their analysis of data sets representing 26,663 children from 10 cohorts in eight countries to calculate prevalence rates of wheeze and asthma by child age. The found strong variations in asthma prevalence (from 1.72% in Germany to 13.48% in England) and the prevalence of wheeze (from 9.82% in Greece to 55.37% in Spain). 

Using the BioXM platform, they were able to attribute the variations to diagnostic rather than natural confounding factors supported by harmonized data on maternal education, parental smoking, parental asthma, pets, allergic rhinitis, eczema and wheeze severity collected across different cohorts and languages. Visit the Biomax Knowledge Library to read the full paper.

TELEMED 2017

6 – 7 July

Vertretung des Freistaates Bayern beim Bund | Berlin, Germany

Digital Health and Care Congress 2017

11 – 12 July
The King's Fund, Cavendish Square | London, UK

SIMB Annual Meeting

30 July – 3 August
Sheraton Denver Downtown | Denver, Colorado, USA

 16. Europäischer Gesundheitskongress

12 – 13 October
München Hilton | Munich, Germany